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The relationship between lipid peroxidation, antioxidant defense and diabetic osteopenia remains unclear. 
This study evaluated the relationship among lipid peroxidation index, antioxidant defense parameters 
and bone metabolism in a premenopausal diabetic model using measures including thiobarbituric acid-
reactive substances concentration (TBARS) and reduced glutathione (GSH) content in brain homogenates, 
histomorphometric analysis, biomechanical testing and bone mineral density (BMD). Female Wistar 
rats with regular estrous cycle were divided into two groups: Group 1: control rats (n = 15) and Group 
2: diabetic rats (n = 15). Diabetes was induced by alloxan and confirmed by glycemia ≥250 mg/dL. The 
lipid peroxidation index, measured by TBARS concentration, showed a significant increase (p<0.05) 
in diabetic animals in comparison to control animals. However, the antioxidant parameter measured by 
GSH content, was significantly lower (p<0.05) in diabetic animals. Histomorphometric analysis showed a 
significant increase (p<0.05) in femoral trabecular separation together with a significant decrease (p<0.05) 
in trabecular thickness, and reduced trabecular bone volume in diabetic rats. Moreover, biomechanical 
testing and BMD values were significantly lower (p<0.05) in the diabetic group. Thus, our results 
demonstrated that increased lipid peroxidation and altered antioxidant defense could be related to the 
development of oxidative stress and diabetic osteopenia in premenopausal rats.
Uniterms: Oxidative stress. Lipid peroxidation. Diabetes mellitus. Diabetic osteopenia/experimental study. 
A relação entre peroxidação lipídica, defesa antioxidante e osteopenia diabética permanece obscura. 
Este estudo avaliou a associação entre índice de peroxidação lipídica, parâmetro de defesa antioxidante 
e metabolismo ósseo em um modelo diabético pré-menopausa através de medidas como a concentração 
de substâncias reativas ao ácido tiobarbitúrico (SRAT) e conteúdo de glutationa reduzida (GSH) no 
homogenato cerebral, análises histomorfométricas, teste biomecânico e densidade mineral óssea (DMO). 
Ratos Wistar fêmeas com ciclo estral regular foram distribuídos em dois grupos: Grupo 1 - ratas controle 
(n = 15) e Grupo 2 - ratas diabéticas (n = 15). O diabetes foi induzido pela aloxana e confirmado pela 
glicemia ≥250 mg/dL. O índice de peroxidação lipídica, medido pela concentração de SRAT, demonstrou 
um aumento significativo (p<0.05) nos animais diabéticos, em relação aos animais controle. Entretanto, 
o parâmetro de defesa antioxidante, mensurado pelo conteúdo de GSH, foi reduzido significativamente 
(p<0.05) nos animais diabéticos. As análises histomorfométricas mostraram um aumento significativo 
(p<0.05) da separação trabecular do fêmur, associado à diminuição significativa da espessura trabecular 
(p<0.05) e volume ósseo trabecular reduzido nas ratas diabéticas. Além disso, o teste biomecânico, 
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medido pela força máxima, e valores de DMO foram reduzidos significativamente (p<0.05) no grupo 
diabético. Dessa maneira, nossos resultados demonstraram que a peroxidação lipídica aumentada e 
defesa antioxidante modificada podem estar relacionadas ao desenvolvimento do estresse oxidativo e 
osteopenia diabética em ratas pré-menopausadas. 
Unitermos: Estresse oxidativo. Peroxidação lipídica. Diabetes mellitus. Osteopenia diabética/estudo 
experimental. 
INTRODUCTION
Bone is formed and reabsorbed continuously, start-
ing in the embryo and continuing throughout adult life. 
Bone homeostasis is regulated by the balance between 
bone matrix formation by osteoblasts and resorption 
by osteoclasts (Rho et al., 2004; Boyce, Xing, 2008). 
In general, disturbances in inflammatory cytokines and 
hormones cause an imbalance between osteoblasts and 
osteoclast activities and can result in skeletal osteopenia 
and osteoporosis (McCabe, 2007). 
There is considerable interest in discovering the 
factors involved in the control of osteoclasts, and thus 
osteoporosis, such as the receptor activator of NF-kB 
(RANK), RANK ligand (RANKL), and osteoprotegerin 
(OPG) (Rasmusse et al., 2006; Wada et al., 2006). The 
binding of RANKL to its receptor RANK provides the 
crucial signal to drive osteoclast development from hae-
matopoietic progenitor cells as well as to activate mature 
osteoclasts. OPG negatively regulates RANKL binding to 
RANK and therefore inhibits bone turnover by osteoclasts 
(Boyce, Xing, 2008). Since increased osteoclast activity 
is observed in patients with osteoporosis, metastasis or 
rheumatoid arthritis, the RANK-RANKL-OPG axis ap-
pears to be the most relevant therapeutic target for all bone 
diseases (Kearns et al., 2008).
Resorption events have been linked to numerous 
factors other than cytokines and hormones, such as growth 
factors and reactive oxygen species (ROS) formation ei-
ther in the bone microenvironment or in the osteoclastic 
precursors of the monocyte-macrophage lineage (Bai et 
al., 2004; Thrailkill et al., 2005b). Over the last decade, 
evidence has accumulated of ROS participation in bone 
resorption, with a direct contribution of osteoclasts gen-
erating high concentrations of superoxide anion (O2-) and 
hydrogen peroxide (H2O2) (Muthusami et al., 2005; Bai et 
al., 2006). However, the mechanisms by which ROS par-
ticipate in accelerating the destruction of calcified tissue 
and hence bone resorption have not been fully explained 
(Muthusami et al., 2005; Ding et al., 2006). Moreover, the 
effect of ROS on osteoblastic function remains unclear 
(Ding et al., 2006). It has been demonstrated that osteo-
blasts produce antioxidants such as glutathione peroxidase 
(GPx) to protect against ROS, but they also produce tumor 
necrosis factor-a (TNF-a), which is involved in bone 
resorption (Isomura et al., 2004; Janssens et al., 2005). 
Any loss of osteoblastic activity increases osteoclastic 
activity or osteocyte death by necrosis or apoptosis. This 
phenomenon could lead to osteoporosis, characteristic 
of lower bone mineral density (BMD), and render bone 
weaker and more likely to fracture (Janssens et al., 2005).
In addition, several risk factors for osteoporosis, 
such as diabetes mellitus (Ding et al., 2006; Léger et al., 
2006) and estrogen deficiency (Godsland, 2005; Muth-
usami et al., 2005) are associated with increased oxidative 
stress. In diabetes mellitus, persistent hyperglycemia may 
cause oxidative stress induced by a variety of mechanisms 
including glucose autoxidation and accelerated glycation 
reaction, with the formation of glucose-derived advanced 
glycosylation end products (AGEs), which in turn catalyze 
lipid peroxidation (Valko et al., 2007). Moreover, there is 
increased carbonyl stress (Kume et al., 2005), polyol path-
way (Oyama et al., 2006) and protein kinase C-dependent 
activation (Kume et al., 2005). In this sense, increased 
malondialdehyde concentration (MDA), both in patients 
(Martìn-Gallán et al., 2003; Tan et al., 2004; Valko et al., 
2007) and diabetic animals (Stoppa et al., 2006), has been 
reported in plasma, erythrocytes, total blood and diverse 
tissues such as brain, liver, kidney and heart. 
There is also evidence that hyperglycemia may reduce 
antioxidant defense mechanisms by altering antioxidant 
enzymes, impairing glutathione metabolism, and lowering 
concentrations of glutathione and vitamins C, E, A and D 
(Rahimi et al., 2005; Stoppa et al., 2006). Persistent hyper-
glycemia increases polyol pathway flux, as well as ROS 
generation rates and AGEs formation, leading to increased 
GSH oxidation (Oyama et al., 2006). Thus, the association 
between increased oxidative stress and lower antioxidant 
defense has an important role in the pathogenesis of diabetic 
osteopenia (Yamagishi et al., 2005; Ding et al., 2006). Re-
cently, results from our laboratory have demonstrated that 
supplementation with antioxidants, such as Vitamin E, de-
creased oxidative stress and markers of lipid peroxidation, 
and also increased GSH content, representing a prevention 
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and therapeutic effect on bone loss. These results supported 
the vitamin’s role as a nutritional and pharmacologic tool in 
the prevention of osteoporosis.
Considering that our previous report also showed 
progressive bone loss similar to that which occurs in pre-
menopausal women with advanced diabetes (Duarte et 
al., 2005), we suggest that the altered redox balance could 
contribute to the development of diabetic osteopenia. To 
test this hypothesis, we assessed the relationship between 
lipid peroxidation, antioxidant defense parameters and 
bone metabolism in a premenopausal diabetic model 
without insulin treatment. This was based on thiobarbituric 
acid-reactive substances (TBARS) and reduced glutathi-
one (GSH) concentrations in the brain associated with 
histomorphometric analyses, biomechanical testing and 
bone mineral density of the femora, for 120 days after the 
onset of experimental diabetes. 
MATERIALS AND METHODS
Animals
Adult female Wistar rats weighing 200 ± 20 g with a 
regular estrous cycle were obtained from the Animal House 
of the Health Sciences Center of the Federal University 
of Rio Grande do Norte, Natal, Brazil. The animals were 
handled in accordance with the standards of the institutional 
ethics committee of the University Hospital Onofre Lopes 
- UFRN and the Revised Guide for the Care and Use of 
Laboratory Animals (National Research Council, 1996). 
Daily determination of estrous cycle phases was performed 
by the previously described vaginal smear method (Duarte 
et al., 2005). During the experimental period, the animals 
were housed in polypropylene cages under hygienic condi-
tions in the departmental animal house. They were subjected 
to a 12h: 12h light:dark cycle and constant temperature 
(22°C-24°C) and humidity (50%-60%). The animals had 
free access to water and to a standard rat diet (Purina, São 
Paulo, Brazil). Thirty rats were randomly allocated to 2 
experimental groups (15 animals/group) as follows: (1) the 
control group, normal rats treated with vehicle sterile saline 
without alloxan; (2) the diabetic group, alloxan-induced 
diabetic rats without insulin treatment. The animals were 
sacrificed by cervical dislocation on days 1 and 5 after the 
induction, and on days 45, 75 and 120 after the onset of 
experimental diabetes. Three rats were used in both groups 
for each experimentation period.
Induction of diabetes
Experimental diabetes was induced in the animals 
by a single intraperitoneal injection of the pancreatic 
b-cell toxin alloxan monohydrate (Sigma Chemical Co., 
Madrid, Spain) dissolved fresh in sterile saline (0.9% so-
dium chloride), at a dose of 120 mg/kg body weight. This 
dose was determined after performing three consecutive 
pilot experiments to define and standardize the dose for 
the induction and maintenance of diabetes mellitus in the 
model. All pilot experiments were carried out in accor-
dance with the regulations for research involving animals 
(National Research Council, 1996), as well as the previ-
ous publication (Duarte et al., 2005). Equal volumes of 
vehicle were injected into the control rats. On day 0, i.e., 
5th day after induction, blood was collected by tail bleed-
ing and glycemia assayed by a glucose-oxidase method 
using a glucometer (Advantage-Boehringer Mannheim, 
Roche, Indianapolis, USA) and compatible reactive 
test strips. Animals with blood glucose concentrations 
³ 250 mg/dL were considered to be diabetic. The blood 
glucose concentrations were monitored fortnightly by 
capillary glycemia throughout the study to determine the 
hyperglycemic state of the rats. Moreover, clinical signs 
of diabetes such as polyphagia, polydipsia, polyuria and 
body weight loss were also observed. The control group 
injected with saline without alloxan maintained normal 
blood glucose concentrations. After each experimental 
period, rats were weighed and killed, and a blood sample 
was obtained from the abdominal aorta. To avoid any 
possible daily cyclic variations in the measurements, 
the animals were killed between 7:00 and 9:00 am. 
Serum glucose concentration was determined using a 
commercial kit (BioSystems Reagents and Instruments, 
Barcelona, Catalunya, Spain) with an RA-50 spectropho-
tometer (Chemistry System Bayer Diagnostic, Dublin, 
Belfast, Ireland). Whereas experimental work involved 
the determination of parameters related to oxidative 
stress, the animals were not submitted to fasting on the 
day of sacrifice, avoiding the consequent generation 
of reactive species. Accordingly, several studies in the 
literature reinforce this approach (Ohkuwa et al., 1995; 
Çinar et al., 2001). The body weight evolution of the 
animals was monitored throughout the 120 days after 
onset of diabetes, on day 0 and at 15-day intervals.
Preparation of brain tissue homogenates 
The brain was perfused with ice-cold 0.9% saline 
in situ, removed and the frontal lobe divided into two 
parts, which were weighed, washed and homogenized 
with specific buffers. The homogenates were centrifuged 
at 1000 g for 4 min at 4 °C (Multispeed Centrifuge PK 
121R Refrigerated version; ALC, Cologno Monzese, MI, 
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Italy). The lipid peroxidation index in brain homogenate 
was determined by the concentration of thiobarbituric 
acid reacting substances (TBARS) and was expressed in 
terms of TBARS (nmol/g tissue) (Bird, Draper, 1984). In 
addition, the antioxidant parameter was also determined in 
brain homogenate by reduced GSH content and expressed 
as mmol GSH/L-1 (Beutler et al., 1963). The concentra-
tions of TBARS and reduced GSH content were measured 
with an RA-50 spectrophotometer (Chemistry System 
Bayer Diagnostic, Dublin, Belfast, Ireland). These assays 
were performed in triplicate in diabetic and control rats 1 
and 5 days after induction, and 45 and 75 days after onset 
of experimental diabetes.
Histology and histomorphometric analysis
The left femora of each animal, at 1 and 5 days 
after induction and 45, 75 and 120 days after onset 
of experimental diabetes, was fixed in 10% formalin, 
processed after immersion in 7.5% nitric acid and 
embedded in paraffin following standard procedures. 
Longitudinal sections (5 to 7 microns) were stained 
with hematoxylin and eosin. Sections were selected for 
analysis to represent a central gap location. Histomor-
phometric parameters of the left femora were the result 
of the means of four measurements of trabecular separa-
tion (Tb.Sp, μm) and trabecular thickness (Tb. Th, μm) 
and trabecular bone volume (BV/TV, %) obtained from 
the metadiaphyseal region, using a Nikon Lobophot 
microscope equipped with a 10X magnification ocular 
lens (Nikon, Tokyo, Japan). The results were reported in 
mm (Duarte et al., 2005). To analyze the percentage of 
the area occupied by trabecular bone and intertrabecu-
lar bone marrow, photomicrographs were taken of the 
femoral metadiaphyseal region at 200X magnification. 
These photographs were analyzed using Photo Studio 
Version 2.0 SE (Tiling 3D grid, medium grid size) by 
the Delesse principle (Duarte et al., 2005). All param-
eters complied with the guidelines of the nomenclature 
committee of the American Society of Bone and Mineral 
Research (Hamada et al., 2007).
Biomechanical testing
The bone mechanical property was evaluated using 
the right femoral of each animal, at 1 and 5 days after 
induction, and 45 and 120 days after onset of experi-
mental diabetes, for a maximum load test representing 
the maximum compressive force applied until fracture. 
The biomechanical parameter was tested using an Instron 
mechanical testing apparatus (Model 4444; Instron Corpo-
ration, Canton, MA, USA), and the compressive loading 
speed used in all tests was 10 mm/min. The results were 
reported as Maximum Load (N) (Reddy et al., 2001).
Bone mineral densities
The BMDs of the total and metadiaphyseal bone 
regions of the right femoral were scanned at 1 and 5 days 
after induction, and 45 and 120 days after onset of expe-
rimental diabetes. These densitometries were measured 
by DXA, using a Lunar DPX (System no. 6647, software 
version 3.6z; Lunar Radiation Corp., Madison, WI, USA) 
adapted for measuring small animals. All scans were 
performed by a licensed radiology technician, using the 
same instrument as previously described (Duarte et al., 
2005).
Statistical analysis
Statistical analyses of the data were performed using 
Statistica software, Version 6.0 (StatSoft Inc., Tulsa, OK, 
USA). The trabecular bone volume value is expressed in 
percentages. All other values are reported as mean ± SD. 
Statistical significance was determined by 1-way analysis 
of variance (ANOVA), which was followed by Tukey’s 
test. The significance levels were defined by p < 0.05.
RESULTS
Blood glucose concentrations and body weight
Mean changes in blood glucose concentrations 
and body weight of the control and diabetic groups are 
shown in Table I. As expected, a significant increase in 
blood glucose was observed in the diabetic rats compared 
to control rats throughout the experimental period (p < 
0.05). Moreover, the diabetic rats also showed other signs 
and symptoms commonly associated with type 1 diabetes 
mellitus, such as polyphagia, polydipsia and polyuria. 
Body weight was significantly reduced in alloxan-induced 
rats compared to control rats on days 75 and 120 after the 
onset of diabetes (p < 0.05). Thus, these data show that 
hyperglycemia in the diabetic group was consistent and 
not transitory.
Oxidant and antioxidant analysis
The oxidant and antioxidant analyses of brain ho-
mogenate are shown in Table I. TBARS concentration, 
an important marker of lipid peroxidation, was slightly 
elevated at the onset of experimental diabetes, and incre-
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ased in a time-dependent manner (p < 0.05). On day 75, 
diabetic rats showed a statistically significant increase in 
TBARS concentration compared to control rats. A statis-
tically significant decrease was observed in the reduced 
GSH content in diabetic animals compared to control 
animals during the same experimental period (p < 0.05). 
No correlation was found between glycemia and TBARS 
concentrations or between glycemia and GSH content. 
These results may indicate increased lipid peroxidation 
and altered antioxidant defense.
Histomorphometry measurements
Histomorphometric changes are shown in Table II. A 
progressive loss of bone mass was observed in the femoral 
histomorphometry of diabetic rats compared to control rats 
throughout the experimentation period (Figures 1, 2 and 
3). Accordingly, the femoral trabecular separation (Tb.Sp, 
μm) was signifi cantly increased (p<0.05) and femoral tra-
becular thickness (Tb. Th, μm) was significantly decreased 
(p<0.05) in diabetic rats compared to the control group. 
In addition, these histomorphometric changes were also 
accompanied by a decrease (p<0.05) in trabecular bone 
volume (BV/TV, %) in diabetic rats during the same pe-
riod. No correlations were found between glycemia and 
histomorphometry measurements. Taken together, these 
results demonstrated low bone turnover resulting from 
an imbalance between bone formation and resorption in 
diabetic premenopausal rats. 
Biomechanical properties
Table II shows the extent of alterations in the biome-
chanical properties of the diabetic femoral. The maximum 
femoral load was significantly lower (by about 25%) in 
alloxan-induced rats than in the control rats on day 120 
after onset of diabetes (p < 0.05). No correlation was found 
between glycemia and maximum femoral load. This data 
supports the observation that the experimental diabetic 
state is associated with mechanical bone deterioration, 
resulting in bones with altered biomechanical properties 
similar to that shown in patients with diabetes mellitus.
Bone mineral densities
The BMDs of the control and diabetic groups are 
shown in Table II. The BMD of the femora was significantly 
lower in the diabetic group throughout the experimental study 
compared with the control group (p < 0.05). Furthermore, 
the decrease in BMD of the femora was greater in the me-
tadiaphyseal region than in the total region in diabetic rats. 
No correlations were found between glycemia and BMD 
measurements. These results also demonstrated a progressive 
decrease of bone mass in the diabetic premenopausal rats.
DISCUSSION
The existence of osteopenia and osteoporosis has 
been increasingly recognized as a complication of diabe-
TABLE I - Glucose, body weight, oxidant and antioxidant parameters in the brain of premenopausal Wistar rats
Variables CONTROL (days) DIABETIC (days)
1  5  45 75 120 1  5 45 75 120
Blood 
glucose 
(mg/dL)
146.8±13.7 145.6±14.1 148.3±25.5 196.7±13.2 190.5±31.0 503.8±51.5* 324.8±5.6* 352.6±26.1* 294.2±38.3* 543.2±31.6*
Body 
Weight
(g)
210±17.0 207±11.0 210±7.0 233±5.0 215±5.0 190±10 198±7 190±10 180±10* 180±5*
TBARS 
(nmol/g 
tissue)
56.1±4.9 _ 57.1±5.0 124.3±11.1* _ 63.5±8.9 _ 62.1±7.6 167.6±16.3** _
GSH 
(GSH/L-1)
1.2±0.0 _ 1.0±0.1 1.1±0.1 _ 1.4±0.0 _ 1.2±0.1 0.81±0.0** _
Data are expressed as mean ± SD (n = 15 rats in both groups). Three rats were used in both groups for each experimental period 
(days 1 and 5 after induction with alloxan and days 45, 75 and 120 after the onset of experimental diabetes). TBARS indicate 
thiobarbituric acid reacting substances; GSH, reduced glutathione. 
* p < .05 by 1-way-ANOVA followed by Tukey’s test when values are compared with control group
** p < .05 by 1-way-ANOVA followed by Tukey’s test when values are compared with control and diabetic groups
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tes mellitus. However, the timing of the onset of diabetic 
bone disease remains somewhat controversial (Kemink et 
al., 2000; Thrailkill et al., 2005a; Duarte et al., 2005). In 
this context, many authors believe that diabetes-induced 
oxidative stress is a factor in the evolution and progression 
of diabetic complications (Ding et al., 2006; Hamada et 
al., 2007). Thus, oxidative stress has been suggested as a 
common pathway linking diverse mechanisms to the pa-
thogenesis of this disorder. We selected alloxan-induced 
diabetic female rats with a regular estrous cycle as a useful 
model for investigating the interrelationship between lipid 
peroxidation, antioxidant defense, type 1diabetes mellitus 
and premenopausal bone loss. This model previously sho-
wed progressive bone loss similar to that which occurs in 
premenopausal women with advanced diabetes (Duarte 
et al., 2005).
According to the World Health Organization (WHO) 
menopause is defined as the permanent interruption of 
spontaneous menstruation for a period of 12 months, a 
result of reduced ovarian follicular activity. Menopause 
is preceded by the menopausal transition, also known as 
perimenopause, which is characterized by irregular mens-
trual cycles or a prolonged period of amenorrhea of more 
than 12 months. The period preceding the perimenopause, 
where there are regular menstrual cycles, is known as pre-
menopause or reproductive period (WHO, 1996; Blake, 
2006; Lund, 2008).
The female sexual cycle has characteristics similar 
to the estrous cycle of other species, including rodents. In 
rats, the cycle is characterized as proestrus, estrus, metes-
trus and diestrus. The ovulation occurs from the beginning 
of proestrus to the end of estrus. From the onset of sexual 
maturity up to the age of 12 months, the mean cycle leng-
th in the female rat is 4 days, and this short cycle length 
makes the rat an ideal animal for investigation of changes 
occurring during the reproductive cycle (Papanicolaou, 
1933). 
The phases of the estrous cycle are identified by his-
tological examination of vaginal smears, since this consti-
tutes an accurate, sensitive and fast method allowing phase 
identification without sacrificing the animal (Martins et al., 
2005). In this study, the model used showed maintenance 
of a regular estrous cycle, determined by vaginal smears 
(Duarte et al., 2005; Martins et al., 2005).
The regular estrous cycle of rats is consistent with 
the condition of regular menstruation of the pre-meno-
TABLE II - Histomorphometry measurements, biomechanical testing and bone mineral density in femoral of premenopausal Wistar rats
Variables CONTROL (days) DIABETIC (days)
1  5 45 75 120 1  5  45 75 120 
Trabecular
distance 
(mm)
0.10 ± 
0.02
0.14 ± 
0.00
0.16 ± 
0.01
0.17 ± 
0.02
0.22 ± 
0.07
0.11 ± 0.02 0.23 ± 
0.04
0.36 ± 
0.02
0.46 ± 
0.08
0.52 ± 
0.06*
Trabecular 
thickness 
(mm)
0.10 ± 
0.01
0.09 ± 
0.02
0.09 ± 
0.00
0.09 ± 
0.00
0.09 ± 
0.00
0.07 ± 
0.01
0.05 ± 
0.00**
0.04 ± 
0.01**
0.03 ± 
0.00**
0.03 ± 
0.01**
Trabecular 
bone volume 
(%)
78.0 77.7 60.0 55.2 49.0 66.0 64.3 23.0 22.2 20.0
Maximum 
load (N)
862.66 ± 
1.15
_ 818.33 ± 
11.15
_ 821.33 ± 
7.09
834.33 ± 
0.57
_ 673.00 ± 
36.51**
_ 606.66 ± 
18.00**
BMD
Metadiaphyseal 
(g/cm2)
0.12 ± 
0.00
_ 0.13 ± 
0.01
_ 0.11 ± 0.01 0.15 ± 
0.02
_ 0.09 ± 
0.01**
_ 0.08 ± 
0.00**
Total 
(g/cm2)
0.15 ± 
0.01
_ 0.13 ± 
0.00
_ 0.13 ± 
0.01
0.17 ± 
0.02
_ 0.14 ± 
0.01
_ 0.10 ± 
0.08*
Trabecular bone volume value is given as percentage. All other data are reported as mean ± SD (n = 15 rats in both groups). 
Three rats were used in both groups for each experimental period (days 1 and 5 after induction with alloxan and days 45, 75 and 
120 after the onset of experimental diabetes). BMD indicates bone mineral density. BMD was measured by dual-energy X-ray 
absorptiometry method (DXA). 
 * p < .05 by 1-way-ANOVA followed by Tukey’s test when values are compared with control and diabetic groups 
 ** p < .05 by 1-way-ANOVA followed by Tukey’s test when values are compared with control group
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pausal women. Thus, this model may be used to represent 
pre-menopausal osteopenia. In this context, it is important 
report that during commencement of menopause the first 
cycles can become irregular, are sometimes anovulatory, 
and finally disappear. This condition was not observed in 
the animal model used.
In preliminary experiments, to exclude potential 
secondary effects of alloxan treatment, so-called alloxan 
toxicity, we also examined an insulin-treated diabetic 
group. Insulin treatment largely restored general histomor-
phometric measurements, reduced BMD and biomarkers 
of bone metabolism, indicating that the osteopenia in 
alloxan-induced diabetic rats was strictly related to the 
diabetic state (data not shown). In this context, the degree 
of glycemic control (which is directly related to insulin 
sufficiency) has been shown to strongly correlate with 
bone integrity in various diabetic models (Thrailkill et al., 
2005b.). However, this study was not aimed at insulin tre-
atment, but evaluated animals in a state of chronic hyper-
glycemia. Thus, we observed marked hyperglycemia, wei-
ght loss and common clinical signs, such as polyphagia, 
polydipsia and polyuria as previously described (Duarte 
et al., 2005). During the experimental period, it was clear 
that diabetic animals (blood glucose ≥ 250 mg/dL) had 
a higher intake of food and water. This group also had a 
higher urine volume excreted over a period of 24 hours. 
Although several studies have examined diabetic 
osteopenia in experimental models (Thrailkill et al., 
2005a; Hamada et al., 2007), the majority of these invol-
ved postmenopausal female rats. Furthermore, although 
the relationship between oxidative stress and diabetic 
osteopenia has been shown by previous studies (Ding et 
al., 2006; Hamada et al., 2007), the effect of altered redox 
balance on osteoblast activity contributing to the onset of 
diabetic osteopenia remains unclear.
Our results showed a significant increase in TBARS 
concentration in the brain homogenate of diabetic rats as 
early as 24 hours after the onset of diabetes, continuing 
throughout the entire 75-day study, which was considered 
sufficient evidence to demonstrate a significant change 
and the close involvement of the stress condition in the 
development of osteopenia. These results support the 
association of diabetes mellitus with increased lipid pe-
roxidation. Although TBARS were not directly measured 
in cartilage and bone, the results obtained for brain ho-
mogenate suggest that TBARS values for skeletal tissues 
would be higher in diabetic rats compared with control rats 
during the experimental period. A number of studies have 
reported the suitability of brain homogenates as an assay 
system for measuring both oxidative damage and antio-
xidant activity, since the brain is vulnerable to oxidative 
FIGURE 1- Simultaneous demonstration of trabecular 
separation, trabecular thickness, and trabecular bone volume in 
femur sections of control rats (A, C, E) and diabetic rats (B, D, 
F), on day 5 (A, B) after induction of experimental diabetes, on 
day 45 (C, E) and day 120 post-onset of experimental diabetes. 
H&E, X200.
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damage because its membrane lipids are rich in polyun-
saturated fatty acids (Santos et al., 2000; Damasceno et 
al., 2002; Rio et al., 2005). Moreover, it has been reported 
that the brain contains low levels of antioxidants such as 
glutathione (GSH) and vitamin E due to their exhaustion 
during AGEs detoxification produced by cell membrane 
lipid peroxidation (Santos et al., 2000; Damasceno et al., 
2002). In addition, osteoblasts have appreciable amounts 
of polyunsaturated fatty acids and hence are highly sus-
ceptible to oxidative stress. Therefore, altered antioxidant 
defense may induce the predisposition of osteoblasts to 
oxidation and inhibit their activity, resulting in diminished 
rates of protein synthesis (Arjmandi et al., 2002).
There is also experimental evidence that hyperglyce-
mia may disrupt natural antioxidant defense mechanisms 
with marked depletion of GSH content, the most prevalent 
low-molecular weight peptide antioxidant in cells (Cay et 
al., 2001; Arjmandi et al., 2006) and in patients (Martìn-
Gallán et al., 2003; Rahimi et al., 2005). Our results also 
showed significantly decreased GSH content in the brain, 
reflecting the marked increased in lipid peroxidation in ex-
perimental advanced diabetes. In this sense, the combina-
tion of increased concentration of oxidable substrates and 
decreased efficiency of detoxification pathways may cause 
an increase in glycosylation and lipoxidation of tissue 
proteins, contributing to the development of diabetic com-
plications such as osteopenia and osteoporosis. Previous 
results in our laboratory showed that supplementation 
with antioxidants, such as vitamin E, decreased oxidative 
stress and lipid peroxidation markers and increased GSH 
content, thus alleviating diabetic osteopenia. These results 
support the association between oxidative stress and dia-
betes mellitus complications and the beneficial effects of 
antioxidants in the management of diabetic osteopenia.
Bone histomorphometry and biomechanical mo-
difications are important factors related to the risk of 
fracture, given that increased morbidity in orthopedic 
patients with diabetes is well documented (Suzuki et al., 
2004; Thrailkill et al., 2005a). In the current study, our 
histomorphometric analyses showed significant progres-
sive femoral bone loss in premenopausal diabetic rats as 
compared to controls rats. Our results also demonstrated 
that diabetes profoundly affected the histological integrity 
of the bone, due to alterations such as increase in trabecular 
separation together with decreases in trabecular thickness 
and trabecular bone volume that were linearly correlated 
with the duration and severity of this disorder. Thus, we 
demonstrated a state of low bone turnover resulting from 
an imbalance between bone formation and resorption in 
the animal model used. There is also evidence that diabetes 
mellitus leads to decreased bone integrity by significant 
reductions in maximum compressive load, deformation at 
maximum load and energy absorption capacity of diabetic 
bone compared to controls (Reddy et al., 2001). Consistent 
with these reports, our biomechanical analyses indicated 
that diabetes state affected femoral biomechanical integri-
ty by a significant progressive reduction in comprehensive 
maximum load in diabetic bone. Therefore, our results 
once again support the association between diabetes, 
increased lipid peroxidation and decreased GSH content 
in the development of bone histomorphometry and bio-
mechanical changes in a premenopausal diabetic model.
DXA has been the predominant technology used to 
evaluate trabecular bone mass loss both in animal models 
(Fukuharu et al., 2000; Duarte et al., 2005) and in diabetic 
patients (Bridges et al., 2005; Léger et al., 2006). In the 
present study, our results showed a significant decrease in 
femoral diabetic BMD values, measured by DXA, confir-
ming that the evolution time of diabetes has a deleterious 
effect on the metabolically active trabecular bone of pre-
menopausal rats. Recently, several clinical investigations 
also demonstrated that premenopausal women with type 
1 diabetes mellitus show significantly lower femoral neck 
BMD than that of healthy individuals (Hadjidakis et al., 
2006). Whereas the objective of this study was to evaluate 
the relationship between lipid peroxidation index, antio-
xidant defense and bone metabolism, with emphasis on 
histomorphometric analysis, biomechanical testing and 
BMD, there is no serum biochemical analysis associated 
to bone and mineral metabolism. However, according to 
a previous publication (Duarte et al., 2005), a significant 
reduction in serum calcium concentration was observed in 
this animal model compared to controls. Serum phospho-
rus and magnesium concentrations did not differ between 
diabetic and control animals.
Additionally, with the advent of molecular studies, 
sequence variants in the vitamin D receptor (VDR), colla-
gen 1 alpha 1 chain (Col1A1), estrogen receptor, estrogen 
receptor alpha (ESR1), OPG, IL-6 and LDL- receptor-rela-
ted protein 5 (LRP5) genes were all found to be significan-
tly associated with differences in BMD and/or fracture risk 
in multiple replication studies (Arko et al., 2005; Ferrari, 
Rizzoli, 2005). Moreover, these investigations indicate an 
interaction between bone mineral density and/or osteopo-
rotic fractures and their association with complex diseases, 
including diabetes mellitus, hypertension, coronary heart 
disease, cancer, arthritis and other common medical condi-
tions (Ferrari, Rizzoli, 2005). These findings also suggest 
that these gene variants may represent common genetic 
susceptibility factors exerting pleiotropic effects during 
the aging process (Ferrari, Rizzoli, 2005). 
Thus, identification of osteoporosis risk factors, 
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and subsequently of those individuals at highest risk of 
multiple related disorders with increased oxidative stress, 
may prompt prevention strategies able to improve global 
health and optimize medical expenditure in diabetic and/
or aging populations.
CONCLUSIONS
 
We demonstrated the relationship between lipid 
peroxidation, antioxidant defense and diabetic osteope-
nia in premenopausal rats. The results of this work show 
that increased lipid peroxidation and altered antioxidant 
defense may be the key events for developing oxidative 
stress, suggesting a role of oxidative stress in the patho-
genesis of diabetic osteopenia in premenopausal rats. 
Further investigations will be required to determine the 
timing of the onset and the role that oxidative stress plays 
in the progression of diabetic bone disease. Clinical studies 
are needed to screen and monitor diabetic osteopenia in 
premenopausal women and to implement preventive or 
therapeutic interventions, as appropriate.
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